comparemela.com

Latest Breaking News On - Greg mayes - Page 6 : comparemela.com

Reunion Neuroscience Inc Appoints Greg Mayes as President

Bringing a 20-Year Track Record of Success in the Biopharma Industry, Mayes Succeeds Joseph del Moral, Who Assumes the Role of Chairman.

United statesPhil carlson sophia bashfordShana marinoAdvaxis immunotherapiesCompany phaseNeither toronto stock exchangeField trip health wellness ltdStrategic communicationsField trip health ltdReunion neuroscience incRegulation services providerGreg mayesChief executiveAntios therapeuticsEngage therapeuticsEngage therapeutics president

Reunion Neuroscience Names Greg Mayes As President And CEO

(RTTNews) - Reunion Neuroscience Inc. (REUN, REUN.TO) announced Wednesday the appointment of Greg Mayes as President and Chief Executive Officer. .

Advaxis immunotherapiesReunion neuroscience incField trip health wellness ltdGreg mayesChief executiveAntios therapeuticsEngage therapeuticsEngage therapeutics presidentRapid epileptic seizure terminationChief operating officerReunion boardRonan levyField trip healthWellness ltd

Antios Therapeutics Announces Notice of Allowance for U S Patent on Phosphoramidates for the Treatment of Hepatitis B Virus

/PRNewswire/ Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic.

United statesGreg mayesTrademark officeWorld health organizationAntios therapeutics incAntios therapeuticsUnited states patentHepatitisb virusActive site polymerase inhibitor nucleotideAntios chief executive officerAntios therapeuticSustained anti viral efficacy

Antios Therapeutics Announces Notice of Allowance for U S Patent on Phosphoramidates for the Treatment of Hepatitis B Virus

/PRNewswire/ Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic.

United statesGreg mayesTrademark officeWorld health organizationAntios therapeutics incAntios therapeuticsUnited states patentHepatitisb virusActive site polymerase inhibitor nucleotideAntios chief executive officerAntios therapeuticSustained anti viral efficacy

Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV

/PRNewswire/ Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic.

United statesGreg mayesCraig gordonAmzak healthVenture fundCapital groupAntios therapeutics incAntios therapeuticsActive site polymerase inhibitor nucleotideChief executive officerAvego bioscience capitalHeartland healthcareDelos capitalLumira venturesDomain partnersSixty degree capital

vimarsana © 2020. All Rights Reserved.